×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Latest Partner Content

Lung cancer survivors stage a takeover of Lung Cancer Foundation of America’s social media channels on World Lung Cancer Day August 1 to demonstrate what it means to be #livingwithlungcancer.
 
Individuals who were screened for hereditary cancer risk in the past might benefit from getting tested again using today’s more sophisticated panels.
The Multiple Myeloma Research Foundation’s newly launched CureCloud is a registry designed to collect clinical and genomic information about patients. Its goals are to help researchers discover treatments for various subtypes of the disease and let patients know whether they have any of 70 genetic aberrations associated with myeloma.
 
From cancer to COVID-19, our patient stories can help others take sickness and disease seriously.
The DONNA Foundation announced today that DONNA Marathon Weekend and the Fearless Series, encompassing all signature DONNA events, will be presented in a virtual format through spring of 2021.

 
Lidia, who was diagnosed with stage 4 lung cancer in 2016, offers her advice for others who have received a cancer diagnosis.
 
A PCF-funded study of men with prostate cancer in Italy suggests that men with prostate cancer who were taking ADT were 4 times less likely to be infected with the coronavirus than men who were not on ADT (androgen deprivation therapy), and 5 times less likely to die. These new findings are a game-changer and may lead to potential treatments for COVID-19, even in men without prostate cancer.
 
The aim is to explore the magnitude of the problem and give researchers and clinicians new insights to improve the quality of life for women lung cancer survivors.
Regulation changes could eliminate barriers to potentially lifesaving CAR-T cell immunotherapy for patients covered by Medicare or Medicaid.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×